CoreAge Rx vs Enhance MD
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Enhance MD head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 85 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make Enhance MD a bad call — it's best for readers who want to see the whole price ladder before they commit and value dose-flat billing plus routine lab work — and who don't need brand-name or oral options. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Enhance MD | |
|---|---|---|
| Brief Score | 94/100 (A) | 85/100 (B) |
| Semaglutide | $149/mo | $212/mo |
| Tirzepatide | $349/mo | $280/mo |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
Enhance MD: Tiered rates held flat; the $112 first-month teaser resets to $212, and the desk still publishes every step on the ladder.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.